<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34560365</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-8421</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>360</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neuroimmunology</Title>
          <ISOAbbreviation>J Neuroimmunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?</ArticleTitle>
        <Pagination>
          <StartPage>577719</StartPage>
          <MedlinePgn>577719</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2021.577719</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0165-5728(21)00246-0</ELocationID>
        <Abstract>
          <AbstractText>The emergence of the coronavirus 2019 (COVID-19) pandemic has presented an unprecedented global challenge. Vaccines against COVID have been developed to date. Covid-19 has been linked with the development of Guillain-Barre Syndrome (GBS), a rare immune-mediated demyelinating neuropathy. We report three cases of Guillain-Barre Syndrome and one case of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), presenting to a Tasmanian hospital, and review 15 other reported cases and discuss likely immunopathology. Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally.</AbstractText>
          <CopyrightInformation>Crown Copyright © 2021. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Oo</LastName>
            <ForeName>Wai M</ForeName>
            <Initials>WM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Launceston General Hospital, Tasmania, Australia; Department of Neurology, Launceston General Hospital, Tasmania, Australia; Faculty of Medicine, University of Tasmania, Launceston, Tasmania, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giri</LastName>
            <ForeName>Pradeep</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Launceston General Hospital, Tasmania, Australia; Department of Infectious Diseases, Launceston General Hospital, Tasmania, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Souza</LastName>
            <ForeName>Aaron</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Launceston General Hospital, Tasmania, Australia; Faculty of Medicine, University of Tasmania, Launceston, Tasmania, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neuroimmunol</MedlineTA>
        <NlmUniqueID>8109498</NlmUniqueID>
        <ISSNLinking>0165-5728</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="N">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013648" MajorTopicYN="N" Type="Geographic">Tasmania</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">AstraZeneca vaccine</Keyword>
        <Keyword MajorTopicYN="Y">COVID-19</Keyword>
        <Keyword MajorTopicYN="Y">COVID-19 vaccine</Keyword>
        <Keyword MajorTopicYN="Y">Chronic inflammatory demyelinating polyneuropathy (CIDP)</Keyword>
        <Keyword MajorTopicYN="Y">Guillain-Barre syndrome</Keyword>
        <Keyword MajorTopicYN="Y">Inflammatory demyelinating polyneuropathy</Keyword>
      </KeywordList>
      <CoiStatement>There is no conflict of interest to report.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>20</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34560365</ArticleId>
        <ArticleId IdType="pmc">PMC8447540</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jneuroim.2021.577719</ArticleId>
        <ArticleId IdType="pii">S0165-5728(21)00246-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Allen C.M., Ramsamy S., Tarr A.W., Tighe P.J., Irving W.L., Tanasescu R., Evans J.R. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann. Neurol. 2021;90:315–318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34114269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ancona P., Bailey M., Bellomo R. Characteristics, incidence, and outcome of patients admitted to intensive care unit with Guillain-Barre syndrome in Australia and New Zealand. J. Crit. Care. 2018;45:58–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29413724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asbury A.K., Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 1990;27(Suppl):S21–S24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2194422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azam S., Khalil A., Taha A. Guillain-Barré syndrome in a 67-year-old male post COVID-19 vaccination (Astra Zeneca) Am. J. Med. Case Rep. 2021;9:424–427.</Citation>
        </Reference>
        <Reference>
          <Citation>Caress J.B., Castoro R.J., Simmons Z., Scelsa S.N., Lewis R.A., Ahlawat A., Narayanaswami P. COVID-19-associated Guillain-Barré syndrome: the early pandemic experience. Muscle Nerve. 2020;62:485–491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7405390</ArticleId>
            <ArticleId IdType="pubmed">32678460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas M.C. Advances in the diagnosis, pathogenesis, and treatment of CIDP. Nat. Rev. Neurol. 2011;7:507–517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21844897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fokke C., Van Den Berg B., Drenthen J., Walgaard C., van Doorn P.A., Jacobs B.C. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24163275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasan T., Khan M., Khan F., Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Rep. 2021;14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8245439</ArticleId>
            <ArticleId IdType="pubmed">34187803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iadecola C., Anrather J., Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183:16–27. e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7437501</ArticleId>
            <ArticleId IdType="pubmed">32882182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>COVID-19 Map Johns Hopkins Coronavirus Resource Center (jhu.edu) 2021. https://coronavirus.jhu.edu/map.html Available:</Citation>
        </Reference>
        <Reference>
          <Citation>Kaur R.J., Dutta S., Bhardwaj P., Charan J., Dhingra S., Mitra P., Singh K., Yadav D., Sharma P., Misra S. Adverse events reported from COVID-19 vaccine trials: a systematic review. Ind. J. Clin. Biochem. IJCB. 2021:1–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7997788</ArticleId>
            <ArticleId IdType="pubmed">33814753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehmann H.C., Hartung H.P., Kieseier B.C., Hughes R.A. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect. Dis. 2010;10:643–651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20797646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu L., Xiong W., Mu J., Zhang Q., Zhang H., Zou L., Li W., He L., Sander J.W., Zhou D. The potential neurological effect of the COVID-19 vaccines: a review. Acta Neurol. Scand. 2021;144:3–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8250748</ArticleId>
            <ArticleId IdType="pubmed">33779985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lunn M.P., Cornblath D.R., Jacobs B.C., Querol L., van Doorn P.A., Hughes R.A., Willison H.J. COVID-19 vaccine and Guillain-Barré syndrome: let’s not leap to associations. Brain. 2021;144:357–360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7799242</ArticleId>
            <ArticleId IdType="pubmed">33313690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madhi S.A., Baillie V., Cutland C.L., Voysey M., Koen A.L., Fairlie L., Padayachee S.D., Dheda K., Barnabas S.L., Bhorat Q.E., Briner C., Kwatra G., Ahmed K., Aley P., Bhikha S., Bhiman J.N., Bhorat A.A.E., Du Plessis J., Esmail A., Groenewald M., Horne E., Hwa S.-H., Jose A., Lambe T., Laubscher M., Malahleha M., Masenya M., Masilela M., McKenzie S., Molapo K., Moultrie A., Oelofse S., Patel F., Pillay S., Rhead S., Rodel H., Rossouw L., Taoushanis C., Tegally H., Thombrayil A., van Eck S., Wibmer C.K., Durham N.M., Kelly E.J., Villafana T.L., Gilbert S., Pollard A.J., de Oliveira T., Moore P.L., Sigal A., Izu A. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New Engl. J. Med. 2021;384:1885–1898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7993410</ArticleId>
            <ArticleId IdType="pubmed">33725432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao Q., Xu M., He Q., Li C., Meng S., Wang Y., Cui B., Liang Z., Wang J. COVID-19 vaccines: progress and understanding on quality control and evaluation. Signal Transduct. Targeted Therapy. 2021;6:199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8129697</ArticleId>
            <ArticleId IdType="pubmed">34006829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maramattom B.V., Krishnan P., Paul R., Padmanabhan S., Cherukudal Vishnu Nampoothiri S., Syed A.A., Mangat H.S. Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann. Neurol. 2021;90:312–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34114256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathey E.K., Park S.B., Hughes R.A., Pollard J.D., Armati P.J., Barnett M.H., Taylor B.V., Dyck P.J., Kiernan M.C., Lin C.S. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J. Neurol. Neurosurg. Psychiatry. 2015;86:973–985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4552934</ArticleId>
            <ArticleId IdType="pubmed">25677463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarthy N., Giesecke J. Incidence of Guillain-Barré syndrome following infection with campylobacter jejuni. Am. J. Epidemiol. 2001;153:610–614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11257070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrogan A., Madle G.C., Seaman H.E., De Vries C.S. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32:150–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19088488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montalvan V., Lee J., Bueso T., De Toledo J., Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin. Neurol. Neurosurg. 2020;194:105921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7227498</ArticleId>
            <ArticleId IdType="pubmed">32422545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mullard A. COVID-19 vaccine development pipeline gears up. Lancet. 2020;395:1751–1752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7272155</ArticleId>
            <ArticleId IdType="pubmed">32505245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel S.U., Khurram R., Lakhani A., Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep. 2021;14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8070856</ArticleId>
            <ArticleId IdType="pubmed">33888484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poser C.M. Criteria for the diagnosis of the Guillain-Barré syndrome. A critique of the NINCDS guidelines. J. Neurol. Sci. 1981;52:191–199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7310433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray S.T.J., Abdel-Mannan O., Sa M., Fuller C., Wood G.K., Pysden K., Yoong M., Mccullagh H., Scott D., Mcmahon M., Thomas N., Taylor M., Illingworth M., Mccrea N., Davies V., Whitehouse W., Zuberi S., Guthrie K., Wassmer E., Shah N., Baker M.R., Tiwary S., Tan H.J., Varma U., Ram D., Avula S., Enright N., Hassell J., Ross Russell A.L., Kumar R., Mulholland R.E., Pett S., Galea I., Thomas R.H., Lim M., Hacohen Y., Solomon T., Griffiths M.J., Michael B.D., Kneen R. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc. Health. 2021;5(9):631–641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8279959</ArticleId>
            <ArticleId IdType="pubmed">34273304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Razok A., Shams A., Almeer A., Zahid M. Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar. Ann. Med. Surg. (Lond.) 2021;67:102540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8253659</ArticleId>
            <ArticleId IdType="pubmed">34249353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothan H.A., Byrareddy S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 2020;109:102433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7127067</ArticleId>
            <ArticleId IdType="pubmed">32113704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.F., Eddins D.L., Bryan J.A. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am. J. Epidemiol. 1979;110:105–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">463869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song E., Zhang C., Israelow B., Lu P., Weizman O.-E., Liu F., Dai Y., Szigeti-Buck K., Yasumoto Y., Wang G., Castaldi C., Heltke J., Ng E., Wheeler J., Alfajaro M.M., Fontes B., Ravindra N.G., Van Dijk D., Mane S., Gunel M., Ring A., Wilen C.B., Horvath T.L., Louvi A., Farhadian S.F., Bilguvar K., Iwasaki A. Neuroinvasive potential of SARS-CoV-2 revealed in a human brain organoid model. bioRxiv. 2020 doi: 10.1101/2020.06.25.169946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2020.06.25.169946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stowe J., Andrews N., Wise L., Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am. J. Epidemiol. 2009;169:382–388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19033158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Meché F.G.A., van Doorn P.A., Meulstee J., Jennekens F.G.I. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur. Neurol. 2001;45:133–139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11306855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Doorn P.A. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS) Presse Med. 2013;42:e193–e201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23628447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Doorn P.A., Ruts L., Jacobs B.C. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18848313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verboon C., van Doorn P.A., Jacobs B.C. Treatment dilemmas in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 2017;88:346–352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27837102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walling A.D., Dickson G. Guillain-Barré syndrome. Am. Fam. Physician. 2013;87:191–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23418763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willison H.J., Jacobs B.C., van Doorn P.A. Guillain-Barré syndrome. Lancet. 2016;388:717–727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26948435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N., Hartung H.P. Guillain-Barre syndrome. N. Engl. J. Med. 2012;366:2294–2304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22694000</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
